Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Non-Current Deferred Tax Liability (2016 - 2017)

Historic Non-Current Deferred Tax Liability for Lisata Therapeutics (LSTA) over the last 8 years, with Q1 2017 value amounting to $1.1 million.

  • Lisata Therapeutics' Non-Current Deferred Tax Liability rose 1360.91% to $1.1 million in Q1 2017 from the same period last year, while for Mar 2017 it was $1.1 million, marking a year-over-year increase of 1360.91%. This contributed to the annual value of $1.1 million for FY2016, which is 1479.58% up from last year.
  • Latest data reveals that Lisata Therapeutics reported Non-Current Deferred Tax Liability of $1.1 million as of Q1 2017, which was up 1360.91% from $1.1 million recorded in Q4 2016.
  • In the past 5 years, Lisata Therapeutics' Non-Current Deferred Tax Liability registered a high of $19.0 million during Q2 2014, and its lowest value of $932700.0 during Q4 2015.
  • Its 5-year average for Non-Current Deferred Tax Liability is $7.6 million, with a median of $4.1 million in 2013.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first skyrocketed by 36910.66% in 2014, then tumbled by 9486.86% in 2015.
  • Over the past 5 years, Lisata Therapeutics' Non-Current Deferred Tax Liability (Quarter) stood at $4.4 million in 2013, then skyrocketed by 315.06% to $18.2 million in 2014, then plummeted by 94.87% to $932700.0 in 2015, then grew by 14.8% to $1.1 million in 2016, then grew by 4.63% to $1.1 million in 2017.
  • Its last three reported values are $1.1 million in Q1 2017, $1.1 million for Q4 2016, and $1.1 million during Q3 2016.